NCT03921671View on ClinicalTrials.gov

Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 1, 2018

Primary Completion Date

October 9, 2021

Study Completion Date

July 16, 2024

Conditions
Thymic CarcinomaThymoma
Interventions
COMBINATION_PRODUCT

Ramucirumab

Combination of ramucirumab (10 mg / kg) + carboplatin (AUC 5) and paclitaxel (200 mg / m2) in patients with carcinoma thymic (or thymoma B3 with areas of carcinoma), relapsed and / or metastatic, in the first line.

Trial Locations (1)

Unknown

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

All Listed Sponsors
lead

Claudia Proto

OTHER

NCT03921671 - Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT) | Biotech Hunter | Biotech Hunter